Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.

Spain, L; Larkin, J

View/Open

Accepted version (344.4Kb)

Publication Date

2016-06

ICR Author

Larkin, James

Author

Spain, L

Larkin, J

Type

Journal Article

Subject

Humans

Melanoma

Antibodies, Monoclonal

Treatment Outcome

Immunotherapy

Survival Analysis

Clinical Trials as Topic

CTLA-4 Antigen

Antibodies, Monoclonal, Humanized

Programmed Cell Death 1 Receptor

Drug-Related Side Effects and Adverse Reactions

Ipilimumab

B7-H1 Antigen

Nivolumab

Research team

Melanoma and Kidney Cancer

Language

eng

License start date

2016-06

Citation

Immunotherapy, 2016, 8 (6), pp. 677 - 679

Publications Repository